- Federal government must find alternatives to rescheduling hydrocodone combination drugs
- ROUNDTABLE: Pharmacy’s future in sync with technology
- Mylan launches generic version of Prandin
- FDA to recommend rescheduling of opioid painkiller hydrocodone from CIII to CII
- FDA issues sweeping new requirements for long-acting opioids
PITTSBURGH — The Food and Drug Administration has approved a generic treatment for bronchospasm made by Mylan, the drug maker said Monday.
Mylan announced the approval of levalbuterol inhalation solution in the 0.31 mg/3 mL, 0.63 mg/3 mL and 1.25 mg/3 mL strengths. The company has begun shipping the product.
The drug is a generic version of Sunovion's Xopenex inhalation solution, which is used to treat bronchospasm in patients ages 6 years and older with reversible obstructive airway disease.
Various versions of the drug had sales of $438.8 million in 2012, according to IMS Health.